1. Hartman M.L., Clayton P.E., Johnson M.L., Celniker A., Perlman A.J., Alberti K.G.M.M., Thorner M.O. A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans. J. Clin. Invest. 1993, 91: 2453–2462.
2. Bermann M., Jaffe C.A., Tsai W., DeMott-Friberg R., Barkan A.L. Negative feedback regulation of pulsatile growth hormone secretion by insulin-like growth factor I. J. Clin. Invest. 1994, 94: 138–145.
3. Guller H.-P., Zapf J., Froesch E.R. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N. Engl. J. Med. 1987, 317: 137–140.
4. Ghigo E., Gianotti L., Arvat E., Ramunni J., Valetto M.R., Broglio F., Rolla M., Cavagnini F., Muller E.E. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans. J. Clin. Endocrinol. Metab. 1999, 84: 285–290.
5. Chapman I.M., Hartman M.L., Pieper K.S., Skiles E.H., Pezzoli S.S., Hinz R.L., Thorner M.O. Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I (IGF-I): evidence for a suppressive action of free rather than bound IGF-I. J. Clin. Endocrinol. Metab. 1998, 83: 2836–2842.